Avenacy releases generic Lupron

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched leuprolide acetate injection, which is a generic of Lupron.

The medication is indicated for the palliative treatment of advanced prostate cancer. Avenacy’s leuprolide acetate injection is available as a 14-day patient administration kit, which includes one multi-dose vial containing 14 mg per 2.8 ml (1 mg per 0.2 ml), 14 disposable syringes and 28 alcohol wipes.

“The launch of leuprolide acetate injection marks an important milestone for Avenacy as our first product available through mail order and retail pharmacies,” said Jeff Yordon, co-founder and CEO of Avenacy. “As we continue to expand our commercial presence across more settings of care, this launch reflects our broader commitment to increasing access to high-quality injectable therapies, and we look forward to introducing additional products into these channels in the near future.”

[Read more: Avenacy launches doxycycline for injection]

The company will begin shipping the medication to wholesale partners this week. Avenacy is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards, the company noted.

Leuprolide acetate injection had a market value of approximately $49 million for the 12 months ending in March 2025, per IQVIA.

[Read more: Avenacy intros generic Reglan]